PMID- 19005687
OWN - NLM
STAT- MEDLINE
DCOM- 20090903
LR  - 20240109
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 17
IP  - 5
DP  - 2009 May
TI  - Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced 
      nausea and vomiting.
PG  - 563-72
LID - 10.1007/s00520-008-0528-8 [doi]
AB  - GOALS OF WORK: Ginger has been used to treat numerous types of nausea and 
      vomiting. Ginger has also been studied for its efficacy for acute 
      chemotherapy-induced nausea and vomiting (CINV). However, its efficacy for 
      delayed CINV in a diverse oncology population is unknown. MATERIALS AND METHODS: 
      We performed a randomized, double-blind, placebo-controlled trial in 162 patients 
      with cancer who were receiving chemotherapy and had experienced CINV during at 
      least one previous round of chemotherapy. All participants were receiving a 5-HT3 
      receptor antagonists and/or aprepitant. Participants were randomized to receive 
      either 1.0 g ginger, 2.0 g ginger daily, or matching placebo for 3 days. The 
      primary outcome was change in the prevalence of delayed CINV. Secondary outcomes 
      included acute prevalence of CINV, acute and delayed severity of CINV, and 
      assessment of blinding. MAIN RESULTS: There were no differences between groups in 
      the prevalence of delayed nausea or vomiting, prevalence of acute CINV, or 
      severity of delayed vomiting or acute nausea and vomiting. Participants who took 
      both ginger and aprepitant had more severe acute nausea than participants who 
      took only aprepitant. Participants were able to accurately guess which treatment 
      they had received. Ginger appeared well tolerated, with no difference in all 
      adverse events (AEs) and significantly less fatigue and miscellaneous AEs in the 
      ginger group. CONCLUSIONS: Ginger provides no additional benefit for reduction of 
      the prevalence or severity of acute or delayed CINV when given with 5-HT3 
      receptor antagonists and/or aprepitant.
FAU - Zick, Suzanna M
AU  - Zick SM
AD  - Departments of Family Medicine, University of Michigan, Ann Arbor, MI, USA. 
      szick@med.umich.edu
FAU - Ruffin, Mack T
AU  - Ruffin MT
FAU - Lee, Julia
AU  - Lee J
FAU - Normolle, Daniel P
AU  - Normolle DP
FAU - Siden, Rivka
AU  - Siden R
FAU - Alrawi, Sara
AU  - Alrawi S
FAU - Brenner, Dean E
AU  - Brenner DE
LA  - eng
GR  - CN-55124/CN/NCI NIH HHS/United States
GR  - U10 CA074648/CA/NCI NIH HHS/United States
GR  - M01-RR00042/RR/NCRR NIH HHS/United States
GR  - KO7 CA102592-01/CA/NCI NIH HHS/United States
GR  - M01 RR000042/RR/NCRR NIH HHS/United States
GR  - NCI U10CA74648/CA/NCI NIH HHS/United States
GR  - K07 CA102592/CA/NCI NIH HHS/United States
GR  - R21 AT001735/AT/NCCIH NIH HHS/United States
GR  - R21AT0001735/AT/NCCIH NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20081113
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Antiemetics)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Morpholines)
RN  - 0 (Serotonin 5-HT3 Receptor Antagonists)
RN  - 0 (Serotonin Antagonists)
RN  - 1NF15YR6UY (Aprepitant)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiemetics/administration & dosage/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/*adverse effects
MH  - Aprepitant
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Zingiber officinale/*chemistry
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morpholines/therapeutic use
MH  - Nausea/chemically induced/*drug therapy
MH  - Prevalence
MH  - Serotonin 5-HT3 Receptor Antagonists
MH  - Serotonin Antagonists/therapeutic use
MH  - Severity of Illness Index
MH  - Vomiting/chemically induced/*drug therapy
PMC - PMC4131259
MID - NIHMS619439
EDAT- 2008/11/14 09:00
MHDA- 2009/09/04 06:00
PMCR- 2014/08/14
CRDT- 2008/11/14 09:00
PHST- 2008/06/14 00:00 [received]
PHST- 2008/10/15 00:00 [accepted]
PHST- 2008/11/14 09:00 [pubmed]
PHST- 2009/09/04 06:00 [medline]
PHST- 2008/11/14 09:00 [entrez]
PHST- 2014/08/14 00:00 [pmc-release]
AID - 10.1007/s00520-008-0528-8 [doi]
PST - ppublish
SO  - Support Care Cancer. 2009 May;17(5):563-72. doi: 10.1007/s00520-008-0528-8. Epub 
      2008 Nov 13.